LGND - Ligand Pharmaceuticals - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

LGND is currently covered by 6 analysts with an average price target of $120.58. This is a potential upside of $18.39 (18%) from yesterday's end of day stock price of $102.19.

Ligand Pharmaceuticals's activity chart (see below) currently has 122 price targets and 106 ratings on display. The stock rating distribution of LGND is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 69.61% with an average time for these price targets to be met of 263.75 days.

Highest price target for LGND is $160, Lowest price target is $135, average price target is $145.

Most recent stock forecast was given by ROBERT WASSERMAN from BENCHMARK on 23-Dec-2024. First documented stock forecast 12-Feb-2014.

Currently out of the existing stock ratings of LGND, 31 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$135

$32.81 (32.11%)

$135

5 months 8 days ago
(23-Dec-2024)

7/9 (77.78%)

$21.2 (18.63%)

211

Buy

$160

$57.81 (56.57%)

$150

5 months 15 days ago
(16-Dec-2024)

13/15 (86.67%)

$37.66 (30.78%)

549

Buy

$157

5 months 20 days ago
(11-Dec-2024)

22/40 (55%)

$35.75 (29.48%)

461

Buy

$143

$40.81 (39.94%)

$140

5 months 20 days ago
(11-Dec-2024)

0/5 (0%)

$22.64 (18.81%)

Buy

$147

$44.81 (43.85%)

$135

6 months 23 days ago
(08-Nov-2024)

0/2 (0%)

$25.75 (21.24%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is LGND (Ligand Pharmaceuticals) average time for price targets to be met?

On average it took 263.75 days on average for the stock forecasts to be realized with a an average price target met ratio 69.61

Which analyst has the current highest performing score on LGND (Ligand Pharmaceuticals) with a proven track record?

SCOTT HENRY

Which analyst has the most public recommendations on LGND (Ligand Pharmaceuticals)?

Scott Henry works at ALLIANCE GLOBAL PARTNERS and has 7 price targets and 4 ratings on LGND

Which analyst is the currently most bullish on LGND (Ligand Pharmaceuticals)?

Balaji Prasad with highest potential upside - $57.81

Which analyst is the currently most reserved on LGND (Ligand Pharmaceuticals)?

Esther Rajavelu with lowest potential downside - -$36.69

Ligand Pharmaceuticals in the News

Ligand Pharmaceuticals Inc (LGND) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ...

Release Date: May 08, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Ligand Pharmaceuticals Inc (NASDAQ:LGND) reported a 46% increase in top-line revenue and an 11% growth in adjusted EPS for Q1 2025. The company has a strong cash position with over $200 million...

Ligand: Q1 Earnings Snapshot

JUPITER, Fla. (AP) — JUPITER, Fla. (AP) — Ligand Pharmaceuticals Inc. (LGND) on Thursday reported a loss of $42.5 million in its first quarter. On a per-share basis, the Jupiter, Florida-based company said it had a loss of $2.21. Earnings, adjusted for non-recurring costs and stock option expense, were $1.33 per share. The drugmaker posted...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?